If this phase of the study is only about dosing safety and tolerability then that is where the announcement should start and finish.
They mention dosing 13 patients with the agent. They mention 8 interpretable scans.
They also mention 2 patients with artefact and 3 patients with tumour invasion and presumably blocked lymphatic drainage.
That means 7/13 imaged patients had a useful result. Not 7/8.
And if safety and tolerability of the agent was the only point of this phase of the study then why mention the presently limited imaging qualities.
- Forums
- ASX - By Stock
- IBX
- Ann: Phase 1 Study Closure and Preliminary Performance
Ann: Phase 1 Study Closure and Preliminary Performance, page-15
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IBX (ASX) to my watchlist
(20min delay)
|
|||||
Last
3.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.364M |
Open | High | Low | Value | Volume |
3.9¢ | 3.9¢ | 3.8¢ | $2.129K | 54.97K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1180 | 3.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.0¢ | 3625 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1180 | 0.039 |
1 | 10000 | 0.037 |
2 | 23000 | 0.036 |
2 | 264073 | 0.035 |
1 | 42385 | 0.034 |
Price($) | Vol. | No. |
---|---|---|
0.040 | 3625 | 1 |
0.044 | 1422 | 1 |
0.045 | 2730 | 1 |
0.056 | 6320 | 1 |
0.060 | 275 | 1 |
Last trade - 16.10pm 22/08/2024 (20 minute delay) ? |
Featured News
IBX (ASX) Chart |
The Watchlist
SS1
SUN SILVER LIMITED
Gerard O'Donovan, Executive Director
Gerard O'Donovan
Executive Director
SPONSORED BY The Market Online